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Abstract
Background: There is wide recognition that pragmatic randomised trials are the best vehicle for
economic evaluation. This is because trials provide the best chance of ensuring internal validity, not
least through the rigorous prospective collection of patient-specific data. Furthermore the marginal
cost of collecting economic data alongside clinical data is typically modest. UK Clinical Research
Collaboration (UKCRC) does not require a standard operating procedure (SOP) for economic
evaluation as a prerequisite for trial unit registration. We judge that such a SOP facilitates the
integration of health economics into trials.
Methods: A collaboration between health economists and trialists at Bangor University led to the
development of a SOP for economic evaluation alongside pragmatic trials, in addition to the twenty
SOPs required by UKCRC for registration, which include randomisation, data management and
statistical analysis.
Results:  Our recent telephone survey suggests that no other UKCRC-registered trials unit
currently has an economic SOP.
Conclusion: We argue that UKCRC should require, from all Trials Units undertaking economic
evaluation and seeking registration or re-registration, a SOP for economic evaluation as one of
their portfolio of supporting SOPs.
Background
There is wide recognition that pragmatic randomised tri-
als are the best vehicle for economic evaluation [1-4]. This
is because trials provide the best chance of ensuring inter-
nal validity, not least through the rigorous prospective
collection of patient-specific data. Furthermore the mar-
ginal cost of collecting economic data alongside clinical
data is typically modest [2].
Several text books and journal articles define best practice
for economic evaluation alongside clinical trials. How-
ever, meeting the defined standards and integrating health
economics into trial protocols and procedures is still a
challenge. For example Drummond et al add a survival
guide for health economists to the latest edition of their
text book [2]!
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Methods
The health economics team at Bangor University collabo-
rated with the North Wales Organisation for Randomised
Trials in Health [NWORTH], the regional trials unit, in its
application to the UK Clinical Research Collaboration
[UKCRC] in 2007 for full registration, offering health eco-
nomics as an additional methodological capability. This
collaboration led to the development of a standard oper-
ating procedure [SOP] for economic evaluation alongside
pragmatic trials, in addition to the twenty SOPs required
by UKCRC for registration, which include randomisation,
data management and statistical analysis. Though UKCRC
does not require a SOP for economic evaluation as a pre-
requisite for trial unit registration, we judge that such a
SOP facilitates the integration of health economics into
trials. Our recent telephone survey suggests that no other
UKCRC-registered trials unit currently has a similar SOP
available.
We had previously undertaken economic evaluations
alongside pragmatic RCTs [5,6]. So we based this SOP on
previous experience and current health economics
resources. Our SOP needed to cover the range of trials to
which we currently contribute economic evaluation.
These include trials in clinical medicine, for example
COGNATE (trial of endoscopic ultrasonography in gastro-
oesophageal cancer – ISRCTN 01444215) and FolATED
(trial of folate as adjunct to anti-depressant therapy
ISRCTN 37558856) [7]; trials of psycho-social interven-
tions, notably RemCare (trial of reminiscence therapy for
patients with dementia – ISRCTN 42430123); and public
health trials, notably CHARISMA (trial of housing
improvements for children with asthma – ISRCTN
13912429). The current trials all evaluate 'complex inter-
ventions' in many centres by adopting a pragmatic whole-
system approach to trial design and conduct, and hence to
the concomitant design and conduct of economic evalua-
tion [8].
Economists and trialists work closely together to put
health economics at the core of trials co-ordinated from
Bangor. For example we appointed a health economist as
trial manager and as health economist to the RemCare
trial. This has enabled us to integrate economic evaluation
into trial protocol preparation, design of information
sheet and consent form, application for ethical approval,
and early preparation of analysis plans and of publication
policy. In this way we are meeting the defined standards
for the design, conduct and reporting of economic evalu-
ations [1-4].
The Bangor SOP [see Additional file 1] for economic eval-
uation alongside pragmatic trials, summarised in Figure 1,
divides economic evaluation activities into three phases:
those preceding funding, thus requiring the development
and sustainability of a health economics research group,
notably pre-funding protocol development; data collec-
tion and management; and economic and statistical anal-
ysis leading to publication. Phase I ensures that health
economics is integral to the development of rigorous and
comprehensive protocols. Phase II seeks to achieve a com-
prehensive data set in which clinical and economic data
complement each other. Phase III completes the symbi-
otic process of clinical and economic evaluation. This SOP
is being considered for adoption by other trials units in
Wales. The SOP is also available electronically http://
www.bangor.ac.uk/healtheconomics and http://www
.bangor.ac.uk/imscar/nworth
Discussion
SOPs cannot themselves overcome the two main limita-
tions of conducting economic evaluations alongside clin-
ical trials – namely the length of follow-up in a typical
trial and the limited number of treatment options com-
pared [2-4]. Nevertheless, Drummond et al have argued
that standard reporting frameworks for economic evalua-
tion promote transparency, improve comparability of
published studies and stimulate economists to address
challenging methodological issues [2,9]. Similarly, we
have found that the development of a SOP for economic
evaluations alongside pragmatic trials managed by a reg-
istered trials unit improve trial conduct and hence the
validity and generalisability of results. Above all, this
process leads to a research culture in which clinical and
economic findings receive equal credit.
Conclusion
Thus, we argue that UKCRC should require from all Trials
Units undertaking economic evaluation, and seeking reg-
istration or re-registration, a SOP for economic evaluation
as one of their portfolio of supporting SOPs.
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Flowchart illustrating a standard operating procedure for economic evaluation alongside trials Figure 1
Flowchart illustrating a standard operating procedure for economic evaluation alongside trials.
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